NARMAFOTINIB Large-Scale Manufactre Complete
MWN-AI** Summary
Amplia Therapeutics Limited (ASX: ATX; OTCQB: INNMF) has successfully completed the first large-scale manufacture of narmafotinib, yielding approximately 13 kg of the drug, a crucial milestone that enhances the company’s readiness for Phase 3 clinical trials. Transitioning the manufacturing process from a research and development (R&D) environment to commercial production involved extensive collaboration with a contract development and manufacturing organization (CDMO), ensuring that the produced drug meets necessary purity and quality standards.
This large-scale manufacturing campaign has not only provided a sufficient drug supply to facilitate Amplia’s ongoing pancreatic cancer trials but also supports its broader clinical development pipeline for other planned studies. The high-quality production of narmafotinib is a significant advancement in Amplia's efforts to meet phase-appropriate standards and prepare for registrational studies.
Dr. Rhiannon Jones, Amplia’s Chief Operating Officer, emphasized the importance of this achievement, stating that it marks a critical step toward advancing the company’s clinical objectives. The produced active pharmaceutical ingredient (API) will soon be formulated into oral capsules for use in current and upcoming trials.
Narmafotinib is recognized as a best-in-class inhibitor of focal adhesion kinase (FAK), a protein that has gained attention for its role in solid tumors, particularly in pancreatic cancer. The drug is under evaluation in the ongoing ACCENT trial, which has demonstrated promising preliminary outcomes, including a response rate of 35%, surpassing the results of existing therapies. Amplia is actively pursuing additional studies to substantiate narmafotinib's efficacy and enhance patient treatment options in oncology.
MWN-AI** Analysis
The recent announcement from Amplia Therapeutics Limited regarding the successful large-scale manufacture of narmafotinib positions the company favorably in the biotechnology and pharmaceutical sector, particularly in its targeted treatment of pancreatic cancer. Achieving this milestone, with a production of approximately 13 kg of active pharmaceutical ingredient (API), showcases Amplia's readiness to transition from R&D to commercial-scale operations — an essential step towards Phase 3 clinical trials.
For investors and market analysts, several key takeaways can guide strategic decisions regarding Amplia's stock (ASX: ATX; OTCQB: INNMF). First, the integration of processes with a contract development and manufacturing organization (CDMO) not only enhances production efficiency but also demonstrates Amplia's commitment to cost-effective manufacturing practices. The successfully produced API will support ongoing and future clinical trials, thus solidifying the company's clinical development pipeline.
Narmafotinib's potential is underscored by the promising early trial results, achieving a confirmed response rate of 35%—significantly higher than the benchmark's rate of 23%. Such data strengthens the case for narmafotinib as a competitive player in the pancreatic cancer treatment landscape. Given that Amplia is focusing on a significant and underserved medical need, the market opportunity could be substantial.
Investors should monitor Amplia's progress in transitioning this API into commercial dosage forms, as successful outcomes will likely drive stock price appreciation. Furthermore, with a robust pipeline investigating other fibrotic cancers and chronic diseases, Amplia presents a compelling growth opportunity. Thus, a buy-and-hold strategy may prove beneficial for long-term investors, particularly as Amplia approaches registrational studies that could lay the groundwork for product approvals. Ultimately, remaining informed about clinical developments and regulatory milestones will be critical in evaluating investment opportunities within Amplia Therapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Successful completion of the first large-scale manufacture of narmafotinib which produced approx. 13 kg of drug
Successful transition of process and production from an R&D facility to a commercial manufacturing environment - a key step in Phase-3 readiness
Sufficient drug supply to support Amplia’s pancreatic cancer trials and other planned studies, supporting the Company's clinical development pipeline
Melbourne, Australia, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces the successful completion of a large-scale manufacture campaign of narmafotinib to required purity and quality specifications. This milestone marks a significant step towards Phase 3 readiness and represents the culmination of months of process development, preparation and delivery as the Company has transitioned manufacturing from a research and development (R&D) facility to a commercial-ready environment.
Amplia has collaborated closely with its contract development and manufacturing organisation (CDMO) partner to ensure a seamless transition to large-scale production. Importantly, the scale-up has led to production efficiencies and significant cost-savings. The next step will involve converting the approx. 13 kg of drug substance manufactured, known as active pharmaceutical ingredient (API), into oral capsules for use in ongoing and upcoming clinical trials.
This newly manufactured API will support Amplia’s pancreatic cancer trials as well as other potential studies currently in various stages of planning.
Dr Rhiannon Jones, Chief Operating Officer of Amplia, who has overseen the production campaign, commented, “Amplia continues to develop its manufacturing processes to meet phase-appropriate standards as we move towards a registrational study. This successful large-scale API synthesis campaign is an important step in ensuring we are prepared for the next stages of clinical development.”
Narmafotinib is manufactured under GMP (Good Manufacturing Practice), which is an internationally recognised system that ensures medicinal products are consistently produced and controlled according to quality standards. It covers all aspects of the manufacturing process, including hygiene, equipment, documentation, and staff training, providing confidence that the product meets strict safety and quality requirements.
This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.
| Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 | Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 423 139 163 U.S. Media: media@ampliatx.com |
About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn.
About Narmafotinib
Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumors. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the ACCENT trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its primary endpoint in achieving a confirmed response rate of 35%, superior to 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone. An interim median PFS of 7.6 months has also been reported. A second trial – AMPLICITY – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.
FAQ**
How does the successful completion of the large-scale manufacture of narmafotinib impact the overall clinical development timeline for Amplia Therapeutics Ltd INNMF, particularly regarding Phase 3 readiness?
What specific strategies did Amplia Therapeutics Ltd INNMF employ to ensure a seamless transition from R&D to a commercial manufacturing environment for narmafotinib?
With the new API produced, how will Amplia Therapeutics Ltd INNMF effectively manage the drug supply to support ongoing pancreatic cancer trials and other planned studies in the pipeline?
What measures have been taken by Amplia Therapeutics Ltd INNMF to maintain GMP compliance during the large-scale production of narmafotinib, and how will this impact safety and quality in upcoming clinical trials?
**MWN-AI FAQ is based on asking OpenAI questions about Amplia Therapeutics Ltd (OTC: INNMF).
NASDAQ: INNMF
INNMF Trading
7.44% G/L:
$0.0967 Last:
14,277 Volume:
$0.09 Open:
